Full-Time

Senior Maintenance and Utilities Technician

Updated on 9/4/2026

Kyowa Kirin

Kyowa Kirin

1,001-5,000 employees

Global specialty pharma focused on antibodies

Compensation Overview

$35 - $48/hr

+ Annual Bonus Program + Discretionary Profit Sharing + Long-Term Incentive Program

Sanford, NC, USA

In Person

On-site role in Sanford, NC; not hybrid or remote.

Bachelor's, Associate's

Category
General Maintenance & Repair (2)
,

Get referred to Kyowa Kirin

See people who can refer or advise you

Requirements
  • High School Diploma with 3-5 years relevant experience.
  • Associates/Bachelor’s Degree and 1-3 years of relevant experience.
  • Demonstrated proficiency in CMMS platforms such as Dynamics 365 for Enterprise Asset Management, SAP Plant Maintenance, IBM Maximo, or equivalent systems to manage calibration schedules, documentation, and asset history.
  • Ability to collaborate effectively with internal stakeholders and service partners to deliver high-quality calibration and maintenance solutions.
  • Strong written and verbal communication skills to ensure accurate documentation and effective coordination across teams.
  • Strong organizational skills and attention to detail to maintain data integrity, ensure compliance, and achieve audit readiness.
  • Demonstrated ability to develop, coordinate, and execute planned shutdowns, ensuring adherence to timelines, safety protocols, and operational requirements.
  • Must be able to work in a regulated manufacturing environment, including construction/start-up phases, with appropriate personal protective equipment.
  • Reasonable accommodation will be provided as required by law.
  • Up to 5% domestic travel may be required based on business needs.
  • This position is on-site in Sanford, North Carolina and is not a hybrid or remote role.
  • Must be able to perform the physical requirements of the role, including occasionally lifting up to 50 pounds; Reasonable accommodation will be provided as required by law.
  • This is an essential role to site operations and may require reporting to the facility or remaining on-site during operational or emergency situations to ensure business continuity.
  • On-call availability may be required to support urgent operational needs.
Responsibilities
  • Perform scheduled inspections, preventive maintenance, and corrective repairs on bioprocessing equipment such as bioreactors, centrifuges, and filtration units to ensure optimal performance and reliability.
  • Execute preventive and corrective maintenance on facility utilities, including boilers, chillers, air compressors, WFI water systems, HVAC systems, and other critical infrastructure as required.
  • Proactively diagnose complex equipment malfunctions, conduct timely repairs, and implement long-term solutions to prevent recurrence; escalate unresolved or critical issues to appropriate management or technical experts, providing clear documentation and recommendations.
  • Demonstrate a strong commitment to safety by adhering to all Environmental, Health, and Safety policies and proactively identifying and mitigating potential hazards.
  • Provide technical support for the start-up, commissioning, and turnover of new systems throughout the site, ensuring seamless integration and compliance.
  • Maintain accurate and comprehensive maintenance records in compliance with GMP, FDA regulations, and audit requirements.
  • Collaborate closely with process engineers, quality assurance, manufacturing staff, and other cross-functional teams to resolve technical issues and support operational goals.
  • Mentor and provide technical guidance to other technicians and contractors, fostering knowledge sharing and professional development.
  • Document root causes of equipment failures and recommend effective, long-term solutions to enhance reliability and efficiency.
  • Plan and execute site shutdowns effectively, ensuring minimal disruption to operations while maintaining safety, compliance, and schedule adherence.
  • Individual contributor, with responsibility to lead or work with cross-functional project teams.

1) What does this company do? Kyowa Kirin develops specialty pharmaceutical drugs with a focus on nephrology, oncology, and immunology, built on a foundation of fermentation technology and antibody science. 2) How does this company's product(s) work? It uses fermentation-derived biology and antibody-based approaches to create therapies that target kidney disease, cancer, and immune-related conditions, delivered as approved medicines after research, development, and clinical testing. 3) How is this company different from its competitors? It blends deep fermentation and microbiology expertise with antibody technology from its history, plus a global specialty-drug focus, resulting from a merger of Kyowa Hakko Kogyo and Kirin Pharma that combined fermentation know-how with pharmaceutical resources. 4) What is this company's goal? To develop and commercialize innovative treatments that address unmet medical needs in nephrology, oncology, and immunology on a global scale.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Get referred to Kyowa Kirin

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA selected Sanford for PreCheck on June 30, 2026, accelerating biologics launch readiness.
  • Crysvita expanded adult XLH dosing in May 2026, extending treatment uptake and persistence.
  • 2025 revenue reached ¥496.8 billion, and 2026 guidance rises to ¥520.0 billion.

What critics are saying

  • Crysvita sales still dominate; any reimbursement squeeze or safety issue hits 2026 results fast.
  • Sanford slips past 2027, and the FDA PreCheck advantage evaporates into delay and cost.
  • March 2026 leadership turnover, including CFO Motohiko Kawaguchi, disrupts execution and accountability.

What makes Kyowa Kirin unique

  • Crysvita remains the only approved XLH therapy, protecting a rare-disease franchise in 2026.
  • Sanford, North Carolina gives Kyowa Kirin a first U.S. biologics manufacturing base by 2027.
  • Benchling deployment in Tokyo and Fuji formalizes AI-enabled R&D workflows across discovery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

Paid Vacation

Paid Sick Leave

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Hybrid Work Options

Pet Insurance

Tuition Assistance

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-2%
Yahoo Finance
Aug 26th, 2026
Cognizant wins Kyowa Kirin AI R&D deal to implement Benchling platform in Japan

Cognizant Technology Solutions will support Kyowa Kirin in implementing Benchling, an AI-driven R&D platform, at the Tokyo and Fuji Research Parks in Japan. The engagement includes platform setup, data migration, ongoing maintenance, and workflow optimization for drug discovery research. The deal reinforces Cognizant's enterprise-scale AI automation capabilities in life sciences digitalization. However, it is unlikely to shift near-term catalysts around broader AI adoption or risks that AI may erode demand for labour-intensive services. Cognizant's narrative projects $24.9 billion revenue and $3.1 billion earnings by 2029, requiring 5.2% yearly revenue growth. The most optimistic analysts forecast revenue reaching $26.1 billion and earnings of $3.9 billion by 2029, depending on how AI investments translate into higher-margin work.

IT Business Today
Aug 17th, 2026
Kyowa Kirin modernizes with Cognizant and Benchling R&D with AI and automation.

Kyowa Kirin modernizes with Cognizant and Benchling R&D with AI and automation. Last updated: August 17, 2026 12:53 pm Kyowa Kirin has chosen Cognizant and Benchling to support the rollout of Benchling's cloud-based R&D platform at its Tokyo Research Park and Fuji Research Park. The platform brings experimental planning, data collection, AI tools, and workflow automation into one place. Researchers can connect experimental equipment directly to Benchling, allowing data to be captured as structured and searchable records instead of being entered manually. That matters as Kyowa Kirin's research work becomes more complex and its pipeline expands. The company expects the platform to help speed up activities ranging from identifying drug targets to selecting new drug candidates. Researchers will also be able to search past experiments, generate reports, examine relationships between studies, and support molecular design using the platform's analytical and AI capabilities. Cognizant will handle the implementation using Benchling, including platform setup, data migration, deployment, and the ongoing upkeep too. This partnership shows where pharma research and development is headed, more or less, these days. More of the work around data handling and routine processes is being moved into connected digital systems, while AI is being brought closer to the research itself rather than treated as a separate tool. ITBT Staffwriter is an in-house contributor at IT Business Today, responsible for delivering timely News and QuickBytes. The author covers the latest developments across IT, tech, and enterprise solutions to keep readers informed with concise and impactful updates. August 17, 2026

Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding

Cimeio Therapeutics
Dec 10th, 2024
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies

The partnership combines Cimeio's proprietary Shielded Cell and Immunotherapy (SCIP) platform with Kyowa Kirin's expertise in cellular therapies and underscores both companies' commitment to using emerging cell and gene therapy technologies to develop new ways to treat patients.